"AI Conductor transforms clinical development from a series of disconnected manual tasks into a synchronized, intelligent process," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "Our AI doesn't work in isolation. It draws from a wide knowledge base to deliver insights, enforce document consistency across the full trial, and ensure every study is submission-ready from the start."
AI Conductor provides a highly configurable, enterprise-grade workspace that serves as a single source of truth across teams. While trial design traditionally involves fragmented conversations and numerous document iterations, PhaseV's generative AI platform actively drafts study components and offers real-time optimizations. The platform grounds projects in regulatory logic by connecting to internal standard operating procedures (SOPs), historical documents and templates. This creates a shared space where teams can collaborate through granular permissions, inline commenting, and easy version comparisons while maintaining an audit-ready history of every change.
AI Conductor serves as a vital layer within PhaseV's vertical AI platform, orchestrating the ClinOps, Trials, Responses, and Portfolio Optimizers. While these Optimizers help sponsors streamline trial design, maximize site selection and monitoring, identify target patient subgroups, and drive smarter clinical decision-making, AI Conductor guides users through several core capabilities across the trial lifecycle:
- Pre-Trial Authoring & Collaboration: From Synopsis to AI-driven Protocol Authoring, the system ensures regulatory compliance at every step. It aligns Statistical Analysis Planning (SAP) with ICH E9 guidelines and generates CDASH-aligned Case Report Forms (CRFs) directly from visit schedules.
- Post-Data Integration & Processing: AI Conductor manages the full data pipeline through seamless EDC integration and automated data standardization. The platform also handles SDTM mapping and ADaM dataset generation including statistical code to produce publication-ready Tables, Listings, and Figures (TLFs) and Clinical Study Reports ready for FDA submission.
By aligning regulatory requirements with sponsor data and workflows, PhaseV helps ensure every document is accurate and compliant from day one.
About PhaseV
Boston-based PhaseV is leading the next era of clinical development through its integrated, multi-modal AI/ML platform that optimizes every phase of the clinical trial lifecycle. The company's core solutions – including the ClinOps, Trial, Portfolio, and Response Optimizers – enable biopharma sponsors and CROs to select the best assets, indications, and patient populations and then rapidly design, plan, and execute optimized fixed, Bayesian, and adaptive trials. With intelligent, data-driven solutions, PhaseV has delivered significant ROI for over 45 leading pharma and biotech sponsors across multiple therapeutic areas, reducing trial costs by up to 50% and increasing the probability of success by over 30%.
Learn more at www.PhaseVTrials.com and follow us on LinkedIn.
Media Contact:
Ellie Hanson
FINN Partners for PhaseV
[email protected]
Photo - https://mma.prnewswire.com/media/2935893/PhaseV.jpg
Logo - https://mma.prnewswire.com/media/2267452/5868311/PhaseV_logo.jpg
SOURCE PhaseV
Share this article